首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   29464篇
  免费   2256篇
  国内免费   697篇
耳鼻咽喉   53篇
儿科学   691篇
妇产科学   94篇
基础医学   1585篇
口腔科学   299篇
临床医学   5389篇
内科学   13131篇
皮肤病学   35篇
神经病学   475篇
特种医学   874篇
外科学   2708篇
综合类   4056篇
现状与发展   2篇
一般理论   1篇
预防医学   398篇
眼科学   53篇
药学   1737篇
  12篇
中国医学   705篇
肿瘤学   119篇
  2024年   42篇
  2023年   487篇
  2022年   731篇
  2021年   1187篇
  2020年   1143篇
  2019年   1280篇
  2018年   1162篇
  2017年   797篇
  2016年   735篇
  2015年   884篇
  2014年   1963篇
  2013年   1761篇
  2012年   1333篇
  2011年   1633篇
  2010年   1363篇
  2009年   1320篇
  2008年   1473篇
  2007年   1537篇
  2006年   1298篇
  2005年   1207篇
  2004年   957篇
  2003年   874篇
  2002年   755篇
  2001年   716篇
  2000年   566篇
  1999年   586篇
  1998年   507篇
  1997年   531篇
  1996年   404篇
  1995年   358篇
  1994年   347篇
  1993年   286篇
  1992年   292篇
  1991年   258篇
  1990年   228篇
  1989年   169篇
  1988年   168篇
  1987年   161篇
  1986年   153篇
  1985年   138篇
  1984年   144篇
  1983年   107篇
  1982年   97篇
  1981年   67篇
  1980年   57篇
  1979年   49篇
  1978年   39篇
  1977年   17篇
  1976年   16篇
  1973年   13篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
目的 了解基因重组人促红细胞生成素 (r HuEPO)对持续性非卧床腹膜透析 (CAPD)患者心室结构及功能的影响。方法  32例CAPD伴高血压患者 ,其中 1 6例应用降压药物控制血压 ,同时应用r HuEPO纠正贫血 ,1 6例单用降压药物 ,随访 6个月。结果 两组治疗前后差值比较 ,治疗组的LVPWT、E/A与对照组比较有显著差异(P <0 .0 5 )。结论 长期纠正贫血和控制血压有利于透析患者左室结构及功能异常的逆转  相似文献   
72.
A 78-year-old man treated with amiodarone for recurrent ventricular tachycardia, had sequential placement of a bipolar VVI pacemaker and an automatic implantable cardioverter defibrillator (AICD). During defibrillation threshold testing, there was failure to capture of the pacer in the post-shock period. The time of failure to capture appeared energy-related: the greater the energy delivered, the longer the failure to capture. Careful attention will be necessary in constructing combined AICD/pacemaker units.  相似文献   
73.
74.
徐育红  王建安 《浙江医学》2004,26(6):407-409
目的探讨原发性高血压(EH)患者微量白蛋白尿(MCA)与血压及左室重塑的关系.方法 84名EH患者按24h尿微量白蛋白值分为微量白蛋白尿组(MCA组)和正常白蛋白尿组(NMCA组),进行动态血压、心脏超声检测,比较两组动态血压值、左室重量指数(LVMI)及左室重塑的特点.结果 MCA组平均收缩压、平均舒张压、脉压、平均动脉压均高于NMCA组(均P<0.01);MCA组LVMI、左室肥厚与向心性肥厚的发生率均高于NMCA组(均P<0.01),正常构型率低于NMCA组(P=0.01).LVMI与尿微量白蛋白值、平均收缩压、平均舒张压均呈显著的正相关(均P<0.05).结论合并有MCA的EH患者血压较高,LVMI较大,左室肥厚与向心性肥厚的发生率较高.MCA与血压及左室重塑密切相关.  相似文献   
75.
76.
The number of left ventricular assist device (LVAD) implantations is growing as a result of increased waiting periods for cardiac transplantation and the decreased availability of organ donors. Furthermore, the Food and Drug Administration (FDA) has approved permanent LVAD support. After an acute hospitalization, patients with LVADs may need prolonged convalescence in a healthcare facility because they have complex medical needs and are physically disabled. Admission criteria need to be developed as essential patient and nursing competencies need to be defined as a part of a successful LVAD program in an acute rehabilitation center. Acute rehabilitation centers can help patients with LVADs transition to a home setting.  相似文献   
77.
我科自1995年1月至2005年1月共收治原发性脑室出血23例,经双侧侧脑室外引流并脑脊液置换术冶疗取得较好效果,现报道如下。  相似文献   
78.
79.
To investigate the possibility of a long-term applicable left ventricular assist device, a 23 mm outer diameter and 31 g weight implantable aortic valvo-pump was developed. It consists of a rotor and a stator; the rotor has a driven magnets assemble and an impeller, the stator has a motor coil with iron core and a outflow guide vane. The device locates the position of aortic valve, delivers the blood directly from left ventricle to aorta. Neither connecting conduits nor “bypass” circuits are necessary. Therefore, the device has promisingly better antithrombogenicity than other heart pumps. In hemodynamic testing, the pump can produce a blood flow of 7 l/min volume with 50 mmHg pressure increase at 15,000 rpm rotating speed, and at zero flow rate the pump can maintain a diastolic pressure over 80 mmHg at same rotating speed. For further studies the blood compatibility and the durability of the device are of most importance.  相似文献   
80.
Biomechanics     
Therapeutic agents used to treat osteoporosis reduce the incidence of vertebral and nonvertebral fractures in osteoporotic women. The antiremodeling agents, such as the bisphosphonates, prevent bone loss by suppressing the remodeling rate, perhaps increasing bone volume slightly, and increasing mineralization of the tissue. The anabolic agents, of which rhPTH(1–34) is the only one approved, accomplish this in a manner that is almost completely the opposite in terms of biological process. rhPTH(1–34) causes net bone gain by stimulating both modeling and remodeling, by increasing bone volume significantly through direct bone apposition to trabecular and endocortical surfaces, and by reducing the mean degree of tissue mineralization (a natural consequence of enhanced remodeling). Each of these treatments maintains or increases bone strength and is similarly effective at preventing fractures. However, because of their different mode of action, each has different consequences for bone matrix quality (defined here by microdamage accumulation and by the properties of mineral and collagen) and the mechanical properties of the tissue. Although bone's composite nature makes it a relatively tough material—more like fiberglass than glass—the accumulation of damage will nevertheless reduce its residual mechanical properties until the damage is repaired through remodeling. Agents that suppress remodeling are associated with both microdamage accumulation and increased mineralization. The biological importance of damage and mineralization to bone's mechanical properties is still a source of debate.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号